Docetaxel
Treatment for Prostate Cancer
Typical Dosage: 75 mg/m² IV every 3 weeks (with prednisone)
Effectiveness
70%
Safety Score
25%
Clinical Trials
509
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
75 mg/m² IV every 3 weeks (with prednisone)
Time to Effect
1-2 months (symptom improvement)
Treatment Duration
4-7 months (6-10 cycles)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$4,000
Side Effect Mgmt:$8,000
Total Annual:$32,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$71,111
Comparison vs ADT alone
Cost Difference
+$26,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
1 active trial recruiting for Docetaxel in Prostate Cancer
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
NCT04633252RECRUITINGPHASE1, PHASE2
86 participants
INTERVENTIONAL
Bethesda, United States
Started: Feb 23, 2021
Completed Clinical Trials
10 completed trials for Docetaxel in Prostate Cancer
Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer
NCT01796028COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Nice, France
Started: Jan 1, 2013
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00280098COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Prague, Czechia
Started: Jan 1, 2006
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
NCT00268710COMPLETEDPHASE2
INTERVENTIONAL
Started: Feb 1, 2004
CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)
NCT01206036COMPLETEDPHASE1, PHASE2
19 participants
INTERVENTIONAL
Essen, Germany +1 more
Started: Jul 1, 2010
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
NCT00313781COMPLETEDPHASE2
204 participants
INTERVENTIONAL
Los Angeles, United States +17 more
Started: May 1, 2006
PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
NCT00291005COMPLETEDPHASE2
42 participants
INTERVENTIONAL
Tokyo, Japan
Started: Aug 1, 2004
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
NCT00137436COMPLETEDPHASE1, PHASE2
93 participants
INTERVENTIONAL
Harvey, United States +23 more
Started: Oct 1, 2005
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
NCT00032825COMPLETEDPHASE1
674 participants
INTERVENTIONAL
Bethesda, United States
Started: Mar 19, 2002
Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation
NCT00186420COMPLETEDPHASE2
13 participants
INTERVENTIONAL
Stanford, United States
Started: Jul 1, 2003
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
NCT01683994COMPLETEDPHASE1, PHASE2
49 participants
INTERVENTIONAL
Bethesda, United States
Started: Sep 7, 2012
Showing 20 of 535 total trials